干细胞衍生的外泌体微小RNA作为儿科心血管疾病的生物标志物和治疗方法
Stem-Cell Derived Exosomal microRNAs as Biomarkers and Therapeutics for Pediatric Cardiovascular Disease.
作者信息
Wasserman Aaron H, Abolibdeh Bana, Hamdan Reema, Hong Charles C
机构信息
Department of Medicine, Michigan State University College of Human Medicine, East Lansing, MI USA.
Henry Ford Health + Michigan State Health Sciences, Detroit, MI USA.
出版信息
Curr Treat Options Cardiovasc Med. 2025;27(1):32. doi: 10.1007/s11936-025-01088-0. Epub 2025 Apr 9.
PURPOSE OF REVIEW
In recent years, several pre-clinical studies have demonstrated the therapeutic potential of stem cell-derived exosomes in the treatment of cardiovascular disease (CVD). Here, we evaluate their potential as biomarkers for the detection and monitoring of CVD, with a particular focus on pediatric heart disease.
RECENT FINDINGS
Exosomes isolated from stem cell sources, including mesenchymal stem cells (MSCs) and pluripotent stem cells (PSCs), benefit cardiovascular function, inflammatory responses, and angiogenesis in injured and diseased hearts. These exosomes carry a variety of cargo, such as proteins, lipids, and nucleic acids. However, the majority contain non-coding RNA molecules.
SUMMARY
Review of the existing literature for several non-coding RNAs and their relationship to CVD suggests that exosomes containing microRNAs (miRNAs) can serve as promising biomarkers for CVD due to their presence in circulation, ease of isolation, and therapeutic potential. These biomarkers are especially promising as screening and diagnostic tools for the early detection of pediatric and congenital heart disease.
综述目的
近年来，多项临床前研究已证明干细胞来源的外泌体在治疗心血管疾病（CVD）方面的治疗潜力。在此，我们评估它们作为检测和监测CVD的生物标志物的潜力，特别关注小儿心脏病。
最新发现
从包括间充质干细胞（MSC）和多能干细胞（PSC）在内的干细胞来源分离出的外泌体，对受损和患病心脏的心血管功能、炎症反应和血管生成有益。这些外泌体携带多种物质，如蛋白质、脂质和核酸。然而，大多数含有非编码RNA分子。
总结
对几种非编码RNA及其与CVD关系的现有文献综述表明，含有微小RNA（miRNA）的外泌体因其存在于循环中、易于分离和具有治疗潜力，可作为有前景的CVD生物标志物。这些生物标志物作为早期检测小儿和先天性心脏病的筛查和诊断工具尤其有前景。
Zotero 插件